La Inmunoterapia en el manejo del cáncer en el Paraguay

  • Tania Fleitas University of Valencia, INCLIVA Biomedical Research Institute, Department of Medical Oncology. Valencia, España
  • Maria Liz Paciello Hospital 12 de Octubre, Department of Hematology. Madrid, España

Resumen

El mundo enfrenta un problema de salud crítico debido al envejecimiento de las sociedades, con estilos de vida poco saludables, desigualdades socioeconómicas y una población mundial en crecimiento. El cáncer se está convirtiendo en uno de los problemas de salud pública más importantes del mundo. En 2018, se estimaron que 181 millones de personas fueron diagnosticadas con cáncer y 9,6 millones murieron a causa de él. Las predicciones sugieren que 30 millones de personas morirán de cáncer cada año para 2030, de las cuales tres cuartas partes en los países de bajos y medianos ingresos, por tanto, un problema prioritario de salud para el Paraguay.

 

Citas

(1) Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R.L., Torre, L.A. and Jemal, A. (2018), Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 68:394-424. doi:10.3322/caac.21492.

(2) Orange M1, Reuter u2, Hobohm u3. Coley‘s Lessons Remembered: Augmenting Mistletoe Therapy. integr Cancer Ther. 2016 Dec;15(4):502-511.

(3) Ott PA1, Adams S. Small-molecule protein kinase inhibitors and their effects on the immune system: implications for cancer treat- ment. immunotherapy. 2011 Feb;3(2):213-27.

(4) Fukuhara H1, ino Y2, Todo T3. Oncolytic virus therapy: A new era of cancer treatment at dawn. Cancer Sci. 2016 Oct;107(10):1373- 1379.

(5) Hanack K, Messerschmidt K, Listek M. Antibodies and Selection of Monoclonal Antibodies. Adv Exp Med Biol. 2016;917:11-22.

(6) Wang RF, Wang HY. immune targets and neoantigens for cancer immunotherapy and precision medicine. Cell Res. 2017 Jan;27(1):11-37.

(7) Vacchelli E, Eggermont A, Fridman WH, Galon J, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Adoptive cell transfer for anticancer immunotherapy. Oncoimmunology. 2013 May 1;2(5):e24238.

(8) Dunn GP, Bruce AT, ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat immunol. 2002;3(11):991-998.

(9) Rosenberg SA, Lotze MT, Muul LM, et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med. 1985;313(23):1485-492.

(10) Rudnicka D, Oszmiana A, Finch DK, et al. Rituximab causes a polarization of B cells that augments its therapeutic function in NK-cell-mediated antibody-dependent cellular cytotoxicity. Blood. 2013;121(23):4694-4702.

(11) Morales A, Eidinger D, Bruce AW. intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J urol. 1976;116(2):180-183. https://www.iarc.fr/wp-content/uploads/2019/02/pr264_E.pdf

(13) MLA style: Tasuku Honjo – Nobel Lecture. NobelPrize.org. Nobel Media AB 2019. Fri. 27 Dec 2019. https://www.nobelprize.org/prizes/medicine/2018/honjo/lecture/

(14) James P. Allison – Nobel Lecture. NobelPrize.org. Nobel Media AB 2019. Fri. 27 Dec 2019. https://www.nobelprize.org/prizes/medicine/2018/allison/lecture/

(15) Herbst RS, Gordon MS, Fine GD, et al. A study of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors. J Clin Oncol. 2013;31 (suppl): Abstract 3000.

(16) Powles T, vogelzang NJ, Fine GD, et al. inhibition of PD-L1 by MP DL3280A and clinical activity in pts with metastatic urothelial bladder cancer (uBC). J Clin Oncol. 2014;32 (suppl): Abstract 5011.

(17) Ansell SM, Lesokhin AM, Borrello i, et al. PD-1 blockade with nivo- lumab in relapsed or refractory Hodgkin‘s lymphoma. N Engl J Med. 2015;372(4):311–319. doi:10.1056/NEJMoa1411087

(18) Topalian SL, Taube JM, Anders RA, Pardoll DM. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer. 2016;16(5):275–287. doi:10.1038 nrc. 2016.36. https://www.targetedonc.com/publications/special-reports/2014/immunotherapy-issue3/a-brief-history-of-immunotherapy

(20) Jochen Buechner, Marie José Kersten, Miriam Fuchs, Florence Salmon, ulrich Jäger, Chimeric Antigen Receptor-T Cell Therapy Practical Considerations for implementation in Europe. HemaSphere, 2018;2:1.

(21) Jessica Hartmann, Martina Schüßler-Lenz, Attilio Bondanza & Christian J Buchholz. Clinical development of CAR T cells- challenges and opportunities in translating innovative treatment concepts EMBO Molecular Medicine, 2017:1-15.

(22) Yu, P.P., Eton, O. & Garrison, L.P. Challenges in assessing the clinical utility and economic value of immune checkpoint inhibitor therapies of Cancer. j. immunotherapy cancer 7, 235 (2019) doi:10.1186/ s40425-019-0707-9.

(23) Camps Herrero C, Caballero Díaz C, Blasco Cordellat A. Farma coeconomía y los costes de los medicamentos contra el cáncer. Farm Hosp. 2010;34(Supl 1):12-15.

Publicado
2019-12-29
Cómo citar
Fleitas, T., & Paciello, M. L. (2019). La Inmunoterapia en el manejo del cáncer en el Paraguay. Revista Paraguaya De Reumatología, 5(2), 39-42. Recuperado a partir de https://revista.spr.org.py/index.php/spr/article/view/106
Sección
EDITORIAL